Aura Biosciences Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript
Morning and welcome to Cowen's Oncology Innovation Summit. I'm Phil Nadeau, one of Cowen's biotech analysts; and it's my pleasure to moderate our next session with Aura Biosciences. We have with us say Eli de los Pinos, the CEO of Aura.
Questions & Answers
Eli, maybe we'll start with a broad overview. Can you give us a brief description of bel-sar, including a brief introduction to its mechanism of action and the underlying technology platform?
Yes. It's a great pleasure to be here, Phil. Thank you for the invitation. And yes. So Aura is developing a very new class of drugs that we call virus-like drug conjugates. And our first VDC is bel-sar.
And as you can see, bel-sar is a virus-like particle that's conjugated to a novel light-activated drug. And the mechanism of action is as follows.
Because it's light activated and the VDC is very stable, it
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
